Similarly, Piao et al. [193] studied the potential synergistic effect of TSA and BEZ235 (dactolisib), a dual pan-class PI3K and mTOR inhibitor, on the development of non-small-cell lung cancer (NSCLC). This evidence concerns the gene MTOR and non-small cell lung carcinoma.